Cerenovus’ Cereglide 71 Aspiration Catheter Launched in Europe

April 16, 2024—Cerenovus, Inc., part of Johnson & Johnson MedTech, Inc., announced the launch of the Cereglide 71 aspiration catheter in Europe.

According to the company, the Cereglide 71 is a next-generation aspiration catheter equipped with Cerenovus’ TruCourse technology. It is indicated for the revascularization of patients experiencing acute ischemic stroke.

The Cereglide 71 provides direct aspiration of blood clots and for the delivery of compatible stent retrievers—including the company’s Embotrap III revascularization device and the Cerenovus Nimbus geometric clot extractor—into the neurovasculature.

Cerenovus stated that the TruCourse technology used in the Cereglide 71 aspiration catheter increases flexibility of the device, which is designed to deliver smoother navigation and access to clots, even in challenging anatomic conditions. This provides physicians with optimal compatibility, durable delivery, and reliable trackability during thrombectomy procedures.

“The introduction of the Cereglide 71 aspiration catheter in Europe is an important step in endovascular thrombectomy, as it allows swift targeted clot access and removal during stroke treatment,” commented Professor Kyriakos Lobotesis, MBBS, in the Cerenovus press release.

Prof. Lobotesis, who is with Imperial College London, in London, United Kingdom, continued, “With Cereglide 71 aspiration catheter, we can now access occlusion sites and aspirate clots more rapidly and efficiently, maintaining a smooth interaction with stent retrievers when used in coaspiration. This leads to the prompt restoration of blood flow in the patient’s brain, which has the potential to save more lives and improve long-term clinical outcomes.”

The company advised that the device will be included in the next phase of its EXCELLENT Registry, a real-world registry launched in 2018 to study stroke-inducing blood clot removal by mechanical thrombectomy.

Devices within the Cerenovus Stroke Solutions portfolio are developed using the company’s expert stroke science insights from its Neuro Thromboembolic Initiative (NTI). Products developed in the NTI have been tested in models that simulate real-world scenarios and seek to further address clinical unmet needs. The portfolio Cerenovus’ Prowler Select Plus, Emboguard, Cerebase, Embotrap III and Cerenovus Nimbus, stated the company.